Encorafenib plus cetuximab not recommended for previously treated colorectal cancer
Although it meets NICE’s criteria for being a life-extending treatment, the cost-effectiveness estimates are higher than what is normally considered a cost-effective use of NHS resources.
Please sign in or register for FREE
Sign in to OnMedica
Or sign in via